SERPING1 and hereditary angioedema: Multiple trials have shown that treatment with rhC1‐INH significantly and rapidly improves HAE attack symptoms among adolescents and adults with C1‐INH‐HAE.21, 22, 23, 24, 25, 26 Results of the current study are consistent with the rhC1‐INH treatment response in adolescents and adults and support the use of the same dosing regimen for HAE attacks in children (50 IU/kg; maximum, 4200 IU) as currently recommended for adolescents and adults, followed by an additional dose, if needed.